Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Noel Barrett

Showing results (61-70 of 66) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 66 results.
Vaccine|November 15, 2011
Safety and immunogenicity of two different doses of a Vero cell-derived, whole virus clade 2 H5N1 (A/Indonesia/05/2005) influenza vaccinePaul A Tambyah, Annelies Wilder-Smith, Borislava G Pavlova, et al.
The Journal of Infectious Diseases|September 18, 2013
Safety and immunogenicity of a vero cell culture-derived whole-virus influenza A(H5N1) vaccine in a pediatric populationMaikel V W van der Velden, Richard Fritz, Eva Maria Pöllabauer, et al.
The Journal of Infectious Diseases|August 29, 2009
A cell culture (Vero)-derived H5N1 whole-virus vaccine induces cross-reactive memory responsesHartmut J Ehrlich, Markus Müller, Sandor Fritsch, et al.
Plos One|February 27, 2010
A whole virus pandemic influenza H1N1 vaccine is highly immunogenic and protective in active immunization and passive protection mouse modelsOtfried Kistner, Brian A Crowe, Walter Wodal, et al.
Clinical and Vaccine Immunology : CVI|September 5, 2014
A Novel multivalent OspA vaccine against Lyme borreliosis is safe and immunogenic in an adult population previously infected with Borrelia burgdorferi sensu latoNina Wressnigg, P Noel Barrett, Eva-Maria Pöllabauer, et al.
The Lancet. Infectious Diseases|May 14, 2013
Safety and immunogenicity of a novel multivalent OspA vaccine against Lyme borreliosis in healthy adults: a double-blind, randomised, dose-escalation phase 1/2 trialNina Wressnigg, Eva-Maria Pöllabauer, Gerald Aichinger, et al.
Pageof 7

Showing results (61-70 of 66) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 66 results.
Vaccine|November 15, 2011
Safety and immunogenicity of two different doses of a Vero cell-derived, whole virus clade 2 H5N1 (A/Indonesia/05/2005) influenza vaccinePaul A Tambyah, Annelies Wilder-Smith, Borislava G Pavlova, et al.
The Journal of Infectious Diseases|September 18, 2013
Safety and immunogenicity of a vero cell culture-derived whole-virus influenza A(H5N1) vaccine in a pediatric populationMaikel V W van der Velden, Richard Fritz, Eva Maria Pöllabauer, et al.
The Journal of Infectious Diseases|August 29, 2009
A cell culture (Vero)-derived H5N1 whole-virus vaccine induces cross-reactive memory responsesHartmut J Ehrlich, Markus Müller, Sandor Fritsch, et al.
Plos One|February 27, 2010
A whole virus pandemic influenza H1N1 vaccine is highly immunogenic and protective in active immunization and passive protection mouse modelsOtfried Kistner, Brian A Crowe, Walter Wodal, et al.
Clinical and Vaccine Immunology : CVI|September 5, 2014
A Novel multivalent OspA vaccine against Lyme borreliosis is safe and immunogenic in an adult population previously infected with Borrelia burgdorferi sensu latoNina Wressnigg, P Noel Barrett, Eva-Maria Pöllabauer, et al.
The Lancet. Infectious Diseases|May 14, 2013
Safety and immunogenicity of a novel multivalent OspA vaccine against Lyme borreliosis in healthy adults: a double-blind, randomised, dose-escalation phase 1/2 trialNina Wressnigg, Eva-Maria Pöllabauer, Gerald Aichinger, et al.
Pageof 7